• Mashup Score: 1

    Metabolic Bariatric Surgery (MBS) is increasingly gaining ground, given that it constitutes the most effective treatment of obesity and associated health problems, with enduring results and a well-documented safety profile. Nevertheless, certain issues may rise in the medium and long term. Among them, there is a heterogeneous group of complications under the umbrella term “post-bariatric hernia”, including internal hernias, abdominal wall hernias, and hiatal hernias. Internal hernias constitute the most studied category, but evidence on the other categories is not lacking. This chapter will attempt to cover diagnostic, treatment, and preventive aspects in the management of hernia post-MBS following a comprehensive, evidence-based approach. In brief, with regards to the prevention of internal hernias, suturing of all defects is strongly recommended for Roux-en-Y Gastric Bypass (RYGB), but the evidence is less clear when it comes to newer bypass procedures, such as One-Anastomosis/Mini G

    Tweet Tweets with this article
    • Hernia as a Complication of Metabolic Bariatric Surgery #some4surgery #hernia #obesity https://t.co/5XvrhQ0ZLD

  • Mashup Score: 8

    Myelodysplastic morphology of blood cells can be encountered not only in myelodysplastic syndrome (MDS) but also in nonclonal disorders like viral, bacterial, parasitic infections, juvenile rheumatoid arthritis, polyarteritis nodosa, immune thrombocytopenic purpura (ITP), iron deficiency anemia, megaloblastic anemia, dysgranulopoietic neutropenia, congenital neutropenia, cases with microdeletion…

    Tweet Tweets with this article
    • Disorders Mimicking Myelodysplastic Syndrome and Difficulties in its Diagnosis https://t.co/AkmrniRHX9 #MDS https://t.co/KO7I6htXBt

  • Mashup Score: 2

    Baricitinib is a novel Janus kinase (JAK) inhibitor which has recently been included in recommendations for treatment of COVID-19. This chapter is focused on discussing the evidence available regarding the safety and efficacy of use of baricitinib alone or in combination with other therapies for treatment of patients with COVID-19. A systematic literature search was conducted for this purpose to…

    Tweet Tweets with this article
    • Comprehensive full-read review of #Baricitinib trials in treating COVID-19. 24 studies (16 retrospective, 5 prospective, 3 case control) studies & 3 larged RCTs show Bari as 24-38% better than comparators/SOC (few showed no change in mortality) https://t.co/2svMMX4wDw https://t.co/zoSGGZJYui

  • Mashup Score: 3

    Baricitinib is a novel Janus kinase (JAK) inhibitor which has recently been included in recommendations for treatment of COVID-19. This chapter is focused on discussing the evidence available regarding the safety and efficacy of use of baricitinib alone or in combination with other therapies for treatment of patients with COVID-19. A systematic literature search was conducted for this purpose to…

    Tweet Tweets with this article
    • Comprehensive full-read review of #Baricitinib trials in treating COVID-19. 24 studies (16 retrospective, 5 prospective, 3 case control) studies & 3 larged RCTs show Bari as 24-38% better than comparators/SOC (few showed no change in mortality) https://t.co/pps1Du9rEt https://t.co/ZEDiHwZ5po

  • Mashup Score: 4

    Aortic valve disease remains the second most common valvular heart disease worldwide. Surgical aortic valve replacement (SAVR) with mechanical or bioprosthetic valves and transcatheter aortic valve replacement (TAVR) with bioprosthetic valves are both approved therapies for patients with severe aortic stenosis (AS) across all surgical risk categories. On the other hand, SAVR remains the mainstay…

    Tweet Tweets with this article
    • Congratulations to our @CvUnmc fellow @AravJhandMD for leading our Perspective Chapter on 🌟VIV TAVR for Failed Bioprosthetic Valves🌟 @trporter58 #VinayakBapat #ACCEarlyCareer #ACCIC #ACCFIT @IntechOpen @UNMC_IM #UNMCIM #BVF #SVD #VIV #TAVR Link: https://t.co/aYwtvbX25u